摘要
目的:观察非诺贝特微粒化胶囊联合辛伐他汀治疗混合型高脂血症的疗效和安全性。方法:冠心病及有高危因素的混合型高脂血症患者72例,分为两组:辛伐他汀组36例,口服辛伐他汀20mg,每日1次;非诺贝特微粒化胶囊加辛伐他汀组(联合治疗组)36例,在辛伐他汀基础上加服非诺贝特微粒化胶囊200mg,每日1次;两组疗程均为8周。观察治疗前后血脂变化和相关不良反应。结果:①两组治疗后血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)均有改善(P<0.05～<0.01),但联合治疗组治疗后LDL-C和TG改善情况优于辛伐他汀组(P<0.05)。②联合治疗组TC、LDL-C、TG的达标率分别为58.3%、44.4%、50.0%,三项达标率为36.1%,明显高于辛伐他汀组的13.9%(P<0.01)。③两组均没有出现严重不良反应。结论:非诺贝特微粒化胶囊联合辛伐他汀对混合型高脂血症的冠心病及有高危因素患者有较好调脂作用,值得在临床推广应用。
Objective：To observe the clinical effect and toxicity of fenofibrate sustained release pellet capsule plus simvastatin in treatment of combine hyperlipidemia.Methods：Seventy-two patients with combined hyperlipidemia were randomly divided into two groups.The simvastatin group （control group n=36）was treated with simvastatin （20mg/d）.The fenofibrate group （n=36） was treated with fenofibrate sustained release pellet capsule （200mg/d） plus simvastatin （20mg/d）.The therapy time was at least 8 weeks.Results：① The serum level of TC,TG,LDL-C,and HDL-C were significantly reduced after treatment in the two groups.In the fenofibrate group,improvements of TG and LDL were better than those of simvastatin group （P〈0.05 ）;② In the fenofibrate group,the normal rate of serum TC,TG and LDL-C were 58.3%,44.4%,50.0%,separately,and the three markers＇normal rate was 36.1%.The latter was significantly higher than that in the simvastatin group （13.9%,P 〈0.01）;③ No serious side effects were detected in the two groups.Conclusion：Fenofibrate sustained release pellet capsule plus simvastatin are a favourable treatment to combine hyperlipidemia.
出处
《心血管康复医学杂志》
CAS
2010年第1期78-80,82,共4页
Chinese Journal of Cardiovascular Rehabilitation Medicine
